fr   en
Clinical Studies

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2010-07-17
Phase: II
Anouncement: Launch
Biotech: BiondVax Pharmaceuticals (Israel)
Pharma:
Product: multimeric-001 vaccine (universal influenza vaccine)
Disease: influenza
Country: Israel
Other: BiondVax has received the approvals of the Ethics (Helsinki) Committee of both the Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem and the Tel Aviv Sourasky Medical Center for the initiation of Phase II trials that will begin in October 2010.
This trial will evaluate the safety and immunogenicity of BiondVax’s universal influenza vaccine candidate, the multimeric-001. It is designed to include a total of 160 participants, both male and female, 18-49 years old, who will be divided into three groups: a treatment group of 80 participants that will receive the 500mcg adjuvanted formulation of the Multimeric-001 vaccine, and two control groups of 40 participants each, that will receive adjuvanted and non-adjuvanted placebo formulations, respectively.
Screening of the potential participants will commence immediately, with the first administrations of the vaccine expected to take place in October 2010.

BiondVax has recently successfully concluded two Phase I/II clinical trials for the Multimeric-001 vaccine (See clinical_studies and clinical_studies)

BiondVax expects to be able to report headline results from this trial by the end of the second quarter of 2011.